You are here: Home ยป Archives for NASDAQ

Trident and the Ministry of Posts, Telecommunications, and Digital Technology of the Democratic Republic of the Congo Sign an Agreement for the Implementation of the National Digital Identity System

SINGAPORE, Feb. 12, 2025 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (“Trident” or the “Company,” NASDAQ: TDTH), a leading catalyst for digital transformation in technology optimization services and Web 3.0 activation based in Singapore, today announced the signing of an implementation agreement with the Ministry of Posts, Telecommunications, and Digital Technology of the Democratic Republic of the Congo (“DRC” or the “Republic”). This agreement marks the beginning of the deployment of the national digital identity system.

This preliminary collaboration agreement signifies the operational launch of a comprehensive digital identification and authentication platform in the DRC. It formalizes the initial collaboration between Trident and the Democratic Republic of the Congo, transitioning from strategic planning to contractual execution.

The agreement outlines specific deliverables, including the development and deployment of an integrated digital identity verification and authentication system based on a secure infrastructure for delivering government services.

Furthermore, the system will incorporate robust data protection measures aligned with international standards, ensuring the security and confidentiality of citizens’ information. These fundamental elements aim to revolutionize interactions between citizens and the government, marking a major step toward a digitally integrated nation. This technology will also benefit citizens by enhancing the efficiency and security of government services while ensuring user control and consent.

Statements from Leadership

Soon Huat Lim, Founder, Chairman, and Chief Executive Officer of Trident, stated:

“The signing of this agreement represents a crucial milestone in our mission to provide the citizens of the DRC with secure and accessible digital identity services. By working directly with the Ministry of Posts, Telecommunications, and Digital Technology, we will implement advanced digital identity verification and authentication systems that will serve as the cornerstone of the DRC’s digital transformation. This implementation phase will focus on building a robust infrastructure, ensuring that every citizen can securely access government services through a verified digital identity.”

He added:

“The systems we are developing will establish new standards for digital governance in Africa while creating a replicable model for developing nations. This partnership is a prime example of how innovative technology can be leveraged to drive meaningful change in people’s daily lives.”

H.E. Augustin Kibassa Maliba, Minister of Posts, Telecommunications, and Digital Technology of the DRC, commented:

“The Digital Identity System is a key pillar in modernizing our country through digital transformation. With Trident, we will be able to provide our citizens with secure and efficient access to government services while protecting their personal data through advancements in blockchain technology. This partnership demonstrates our commitment to leveraging innovative solutions for the benefit of all Congolese. By implementing this digital transformation, we are not only building infrastructure but also creating new opportunities for economic growth and social inclusion.”

About Trident

Trident is a leading catalyst for digital transformation in digital optimization, technology services, and Web 3.0 activation worldwide based in Singapore. The Company offers commercial and technological digital solutions designed to optimize its clients’ experience with their end–users by promoting digital adoption and self–service.

Tridentity, the Company’s flagship product, is an innovative and highly secure blockchain–based identity solution designed to provide secure single sign–on authentication capabilities to integrated third–party systems across various industries. Tridentity aims to offer unparalleled security features, ensuring the protection of sensitive information and preventing potential threats, thus promising a new secure era in the global digital landscape in general, and in Southeast Asia etc.

Beyond Tridentity, the Company’s mission is to become the global leader in Web 3.0 activation, notably connecting businesses to a reliable and secure technological platform, with tailored and optimized customer experiences.

Safe Harbor Statement

This announcement contains statements that may constitute “forward–looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward–looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. The Company may also make written or oral forward–looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward–looking statements. Forward–looking statements involve inherent risks and uncertainties, including the possibility that a definitive agreement will not be concluded as contemplated under the preliminary collaboration agreement discussed in this announcement, and the possibility that the e–GOV system will not materialize as contemplated under the preliminary collaboration agreement or a definitive agreement if and once concluded. A number of factors could also cause actual results to differ materially from those contained in any forward–looking statement, including but not limited to the following: the Company’s strategies, future business development, and financial condition and results of operations; the expected growth of the digital solutions market; the political, economic, social and legal developments in the jurisdictions that the Company operates in or in which the Company intends to expand its business and operations; the Company’s ability to maintain and enhance its brand. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any obligation to update any forward–looking statement, except as required under applicable law.

Investor and Media Contacts

Investor Relations
Robin Yang, Partner
ICR, LLC
Email: [email protected]
Phone: +1 (212) 321–0602

Media Relations
Brad Burgess, SVP
ICR, LLC
Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1627fdde–b97d–48f2–b2b9–f50149c37570


GLOBENEWSWIRE (Distribution ID 9357153)

Value of AI, Cloud Solutions Reign in Cellebrite’s 2025 Annual Industry Trends Survey

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the release of its sixth annual 2025 Industry Trends Survey. This year’s report explores how public safety professionals use and apply powerful digital investigative solutions to uncover digital evidence in criminal investigations. For the first time, the survey reveals a widespread appetite for artificial intelligence (AI) to assist and simplify investigations, with 80% of respondents acknowledging AI helps automate time–consuming tasks and identify critical evidence faster.

With more than 2,100 responses from examiners, investigators, analysts, prosecutors and agency managers across nearly 100 countries, the survey showed that while three in 10 respondents have seen an uptick in AI–related criminal activity, 64% believe this same technology can be used to reduce crime.

Additional notable insights include:

  • Near–unanimous reliance on digital evidence: For the second time in three years, digital evidence was cited for its high value in investigations. 98% of prosecutors reported digital evidence is pivotal in securing convictions, and more than half of respondents agreed it is more important than DNA.
  • Traction for cloud–based solutions: Public safety professionals are increasingly interested in harnessing the power of the cloud. Nearly 40% of those surveyed are now open to using cloud technologies for evidence storage and sharing, citing its scalability and security advantages – up from 35% last year; while six in 10 investigators still rely on legacy options like USB sticks for data sharing, which are widely recognized as inefficient and invite security risks that could compromise the chain of custody.
  • Overwhelming device and data volumes: With cases typically involving an average of two to five devices and the average data volume doubling over the past two years, 69% of investigative teams reported that they lack the tools and time to adequately review all the case data.

“In an era where bad actors are increasingly sophisticated in covering their digital footprints, law enforcement agencies must embrace advanced technologies to keep pace and protect their communities,” said David Gee, Cellebrite’s chief marketing officer. “Our findings this year underscore the urgency and necessity of integrating responsible AI and cloud solutions into investigative workflows to ensure justice is served efficiently, defensibly and securely.”

For the full 2025 Industry Trends Survey and to learn more about innovative solutions for digital investigations, visit our website.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigation platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Contacts:

Media
Victor Ryan Cooper
Sr. Director of Corporate Communications + Content Operations
[email protected]
+1 404.804.5910

Investors Relations
Andrew Kramer
Vice President, Investor Relations
[email protected]
+1 973.206.7760


GLOBENEWSWIRE (Distribution ID 9356055)

Cellebrite’s Generative AI Innovations Deliver a Powerful Assistant to Expedite Investigations

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 06, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the general availability of Generative Artificial Intelligence (GenAI) capabilities within Guardian, the Company’s SaaS–based evidence management solution.

By incorporating GenAI into Guardian, public safety agencies benefit from AI–driven productivity. Users can now form a more complete picture by quickly summarizing and contextualizing vast amounts of data, such as hours of audio messages or lengthy text message strings. Keywords and thematic direction accelerate an agency’s mission and empowers investigators who are reading, analyzing and validating the data with more insight on where to look next, including:

  • Chat thread summarization – With today’s smartphones containing 60,000 text messages on average, investigators save time reviewing the context of the messages, even if in a foreign language, to help prioritize which threads may be most relevant.
  • Relationship insight – Quickly understanding relationships between people is critical in investigations and this feature is a real value–add when investigating complex crime networks.
  • Browsing history analysis – Often buried and hard to decipher, this component breaks down complex URLs and contextualizes exactly what was searched and when the search was conducted.

“It is impossible to calculate the hours it would have taken to link a series of porch package thefts to an international organized crime ring,” said Detective Sergeant Aaron Osman with Susquehanna Township, Pennsylvania Police Department, who recently piloted the solution. “The GenAI capabilities within Guardian helped us translate and summarize the chats between suspects, which gave us immediate insights into the large criminal network we were dealing with.”

“This innovation marks a significant and tangible milestone in our efforts to accelerate the speed of investigations,” said Ronnen Armon, Cellebrite chief products and technologies officer. “Rather than trying to manually find the proverbial needle in a haystack, the GenAI acts as an assistant and guide to help law enforcement professionals identify powerful digital evidence that can advance an investigation and make communities safer.”

Cellebrite’s annual Industry Trends survey showed that while three in 10 respondents have seen an uptick in AI–related criminal activity, 64% believe this same technology can be used to reduce crime. As a leader in digital investigations, Cellebrite rigorously tested GenAI within Guardian, its native SaaS solution that is helping a growing number of law enforcement agencies easily and securely compile, review and share digital evidence to enhance collaboration. Multiple agencies tested the GenAI features during 2024 as Cellebrite continued to deliver high–impact, customer–driven innovation designed to make digital evidence more accessible, actionable and defensible. This innovation represents the next phase of ethically integrating AI into the Company’s complete Case–to–Closure platform.

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigation platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Contacts:

Media
Victor Ryan Cooper
Sr. Director of Corporate Communications + Content Operations
[email protected]
+1 404.804.5910

Investors Relations
Andrew Kramer
Vice President, Investor Relations
[email protected]
+1 973.206.7760


GLOBENEWSWIRE (Distribution ID 9353626)

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–

–Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025–

–Topline results from pivotal Phase 3 Trial in Immunoglobulin G4–Related Disease (INDIGO) expected year–end 2025–

– Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025–

– Out–licensed greater–China anti–IGF–1R Thyroid Eye Disease programs to Zai Lab –

WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical–stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced its 2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited cash balance as of year–end 2024.

“Based upon the progress achieved across all of our corporate goals and objectives during 2024, we enter 2025 with an opportunity to achieve major value–driving milestones with the anticipated results from our ongoing obexelimab Phase 2 and Phase 3 clinical trials,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. “We are extremely proud of the accomplishments of our dedicated team as we enter the year well–financed and able to focus on execution, and achievement of our key objectives for the year.”

The Company enters 2025 well–capitalized to deliver its key milestones with approximately $350 million in cash, cash equivalents, and short–term investments as of December 31, 2024, 1 which is expected to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.

2024 Accomplishments and Recent Achievements

During 2024, the Company achieved the following objectives and announced a recent business development transaction:

  • Completed enrollment of the Phase 3 INDIGO trial, a global Phase 3 registration–directed, randomized, double–blind placebo–controlled trial of obexelimab in patients with Immunoglobulin–G4 Related Disease (IgG4–RD), the largest clinical trial ever conducted in this patient population.
  • Initiated the Phase 2 MoonStone trial, a Phase 2, multicenter, randomized, double–blind, placebo–controlled trial, to evaluate the efficacy and safety of obexelimab in patients with Relapsing Multiple Sclerosis (RMS).
  • Initiated the Phase 2 SunStone trial, a Phase 2, multicenter, randomized, double–blind, placebo–controlled trial, to evaluate the efficacy and safety of obexelimab to reduce disease activity in patients with Systemic Lupus Erythematosus (SLE).
  • Provided initial data from the Phase 2 SApHiAre trial, a global, multicenter, open–label safety and dose confirmation run–in period (SRP) to evaluate the safety and activity of obexelimab in patients with warm Autoimmune Hemolytic Anemia (wAIHA). Obexelimab achieved clinical proof–of–mechanism by increasing hemoglobin levels and red blood cells, and decreasing LDH and total bilirubin levels. Obexelimab was well tolerated in the SRP.
  • Completed an upsized Series C and initial public offering, raising approximately $458.7 million in aggregate gross proceeds to fund its planned activities for obexelimab and the Company’s growth strategy.
  • Bolstered its leadership team with the appointments of Chief Commercial Officer, Orlando Oliveira, and Chief Legal Officer, Jeff Held.
  • Out–licensed ZB005, a human IgG4 monoclonal antibody designed to bind only to the active form of C1s, for which Zenas held the development and commercialization rights in China, Hong Kong, Macau and Taiwan (Greater China) through an exclusive license with Dianthus.
  • The Company recently out–licensed regional rights to its thyroid eye disease programs, including ZB001, an insulin–like growth factor–1 receptor (anti–IGF–1R) monoclonal antibody, to Zai Lab (Zai).  Zenas received an upfront fee and is eligible to receive milestone payments and royalties in the future, as consideration for an exclusive sublicense to Zai to develop and commercialize ZB001 and related programs in Greater China.

Anticipated 2025 Clinical Milestones for Obexelimab

Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique mechanism of action and self–administered, subcutaneous once–weekly injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Obexelimab has been evaluated in five completed clinical trials in a total of 198 patients who received obexelimab either as an intravenous infusion or as a subcutaneous injection. Obexelimab was well tolerated and demonstrated clinical activity across these five clinical trials, providing the Company an initial clinical proof of concept for obexelimab as a potent B cell inhibitor for the treatment of patients living with certain autoimmune diseases.

During 2025, the Company expects to achieve the following key clinical milestones:

  • Report the 12–week primary endpoint results in the third quarter of 2025 from the Phase 2 MoonStone trial in patients with RMS.

The role of B cells in the pathogenesis of multiple sclerosis including RMS has been demonstrated through the successful clinical development, approval and clinical use of anti–CD20 B cell targeting therapies of other companies, including OCREVUS® (ocrelizumab) and KESIMPTA® (ofatumumab), which selectively deplete CD20–expressing B cells. The Company believes obexelimab’s unique mechanism of action to potently inhibit but not deplete a broader B cell lineage than CD20, nonclinical data, and a subcutaneous injection regimen, supports its potential for the treatment of RMS.

  • Following an initial screening period, patients in the MoonStone trial are being randomized 2:1 to 250 mg of obexelimab or placebo administered as a subcutaneous injection every seven days for a 12–week treatment period.
  • The primary objective of this double–blinded portion of the trial will be to assess the change from baseline in the cumulative number of gadolinium (Gd) enhancing lesions identified on T1–weighted magnetic resonance imaging (MRI).
  • Upon completion of the 12–week period, patients will enter an open–label period where patients on placebo will receive obexelimab treatment for at least three months, and patients initially randomized to obexelimab will continue treatment.
  • Important secondary endpoints during this open–label period include using standardized assessments, novel 3D imaging and biomarkers, including serum neurofilament light chain (NfL), to evaluate the impact of obexelimab on disease progression.

More information on the Phase 2 MoonStone trial (NCT06564311) is available at clinicaltrials.gov

  • Report topline results year–end 2025 from the Phase 3 INDIGO trial in patients with IgG4–RD.

IgG4–RD is a chronic fibro–inflammatory disease that can affect virtually all organ systems, including the pancreas, biliary tract, salivary and lacrimal glands, lungs, and kidneys. Patients with IgG4–RD may present with a single organ involved but more frequently present with multiple organ involvement. As the disease progresses and patients experience new or worsening symptoms (i.e., flares), lesions develop in additional organs and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, which can lead to major irreversible tissue damage and ultimately organ failure. We estimate that the currently diagnosed population of IgG4–RD patients in the U.S. is approximately 20,000, with comparable prevalence rates globally.

Despite the growing recognition of IgG4–RD and advances in the understanding of its pathophysiology, there are no approved therapies for the treatment of this disease and there remains high unmet medical need. The current standard of care is treatment with glucocorticoids (GCs). Although GCs are initially effective, treatment with GCs can often result in various complications and co–morbidities. Most patients can relapse within 12 months of discontinuing GC treatment, and maintenance therapy with GCs has not been shown to prevent recurrence of disease.

The pathogenesis of IgG4–RD suggests that B cell–targeted therapies may provide therapeutic benefit. Although not approved by any regulatory authorities to treat IgG4–RD, certain B cell depleting agents (e.g., rituximab) are occasionally administered to patients with IgG4–RD. However, B cell depleting agents are often associated with infections, including serious opportunistic infections, and can compromise a patient’s ability to mount a response to vaccinations.

The reported evidence for the role of B cells in the pathogenesis of IgG4–RD, the observed effects of B cell targeting agents in previous trials in IgG4–RD, the data from our Phase 2 IgG4–RD trials with obexelimab, and its unique, non–depleting mechanism and once–weekly, subcutaneous injection regimen support its development in patients with IgG4–RD.

  • INDIGO is the largest clinical trial conducted in patients living with IgG4–RD and is designed to evaluate the safety and efficacy of obexelimab in approximately 190 patients with active IgG4–RD and being conducted at approximately 100 sites in 20 countries.
  • Following an initial screening period, patients were randomized 1:1 to 250 mg of obexelimab or placebo administered as a subcutaneous injection every seven days for 52 weeks, followed by an opportunity for eligible patients to continue in an open–label extension period where all patients will receive treatment with obexelimab.
  • The primary efficacy endpoint of INDIGO is the time to first IgG4–RD flare, as determined per protocol by the investigator and the adjudication committee.
  • Secondary endpoints include annualized flare rate, the proportion of patients achieving complete remission, and use and quantity of rescue medication, including GCs.

More information on the Phase 3 INDIGO trial (NCT05662241) is available at clinicaltrials.gov

  • Complete enrollment in 2025 in the Phase 2 SunStone trial in patients with SLE and report topline results in the first half of 2026.

The crucial role of B cells in SLE pathogenesis is well recognized, from producing autoantibodies to abnormal regulation of immune responses. Moreover, SLE is an autoimmune disease characterized by B cell dysfunction, the production of autoantibodies toward cellular and nuclear components, and multiorgan damage caused by immune complex deposition and inflammation within affected tissues. Current treatments are limited in number and modestly effective. Obexelimab has demonstrated clinical activity in a prior Phase 2 double–blind, randomized trial demonstrating proof–of–concept in the overall trial population and increased response in patients who maintained higher systemic exposure to obexelimab, and also in biomarker–defined subpopulations. Coupled with the safety data obtained to date, we believe these data provide support for the development of obexelimab in patients with SLE.

  • Patients with active SLE determined at screening by the investigator and adjudication committee are randomized 1:1 to obexelimab 250 mg or placebo administered as a subcutaneous injection every seven days for 24 weeks.
  • The 250 mg once–weekly subcutaneous injection dose has been selected to maximize the potential for clinical activity as higher systemic exposure (Ctrough) correlated with greater clinical activity in the prior Phase 2 trial in SLE.
  • The primary endpoint is the percentage of responders, defined by BILAG–based Composite Lupus Assessment, with a reduction of SLE disease activity at week 24.
  • Biomarker analysis is planned to be conducted in all patients, including baseline RNA expression profiles to immunophenotype patients and evaluation of their differential responses to treatment.

More information on the Phase 2 SunStone trial (NCT06559163) is available at clinicaltrials.gov

About Zenas BioPharma, Inc.

Zenas is a clinical–stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self–administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.

Forward looking statements

This press release contains “forward–looking statements” which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward–looking statements. In some cases, forward–looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward–looking statements contain these words. Forward–looking statements include, but are not limited to, statements concerning Zenas’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting INDIGO trial topline results, the 12–week primary endpoint data for the MoonStone trial and the anticipated timing of completing enrollment and reporting topline results for the SunStone trial; its growth strategy; the Company’s preliminary unaudited cash, cash equivalents and short–term investments as of December 31, 2024; and cash runway guidance. The forward–looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward–looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the Company’s current indications; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third–party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers, many of which are located outside of the United States, including the Company’s current sole contract manufacturing organization for drug substance and drug product, WuXi Biologics (Hong Kong) Limited, which is located in China; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10–Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward–looking statements in this press release are inherently uncertain, speak only as of the date of this press release and may prove incorrect. These statements are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Because forward–looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, these forward–looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in the forward–looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward–looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward–looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:

Matthew Osborne

Investor Relations and Corporate Communications
[email protected]

Media Contact:

Argot Partners
[email protected]

1 This amount is preliminary and unaudited and is subject to completion of the Company’s financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2024.


GLOBENEWSWIRE (Distribution ID 9353140)

Lantronix Lança LM4, Nova Plataforma Out-of-Band Management Alimentada por IA na Cisco Live

IRVINE, Califórnia, Feb. 05, 2025 (GLOBE NEWSWIRE) — A Lantronix Inc. (NASDAQ: LTRX), líder global de computação e conectividade para soluções de IoT que permitem inteligência de AI Edge, lançará sua nova plataforma LM4 Out–of–Band Management (OOBM) alimentada por IA no Stand A10 durante a Cisco Live, entre 10 e 14 de fevereiro de 2025, na RAI de Amsterdã. O LM4 da Lantronix é o primeiro servidor de console da indústria especificamente projetado, dimensionado e precificado para Quadros de Distribuição Intermediários (Intermediate Distribution Frames – IDFs) e ambientes compactos, como caixas eletrônicos, quiosques e pontos de agregação de rede. Projetado para serviços de saúde, finanças, serviços públicos, telecomunicações, governo, varejo e fabricação, o LM4 oferece recursos de automação, conformidade e segurança cibernética de nível empresarial, aproveitando a tecnologia comprovada em redes militares e financeiras.

“Estamos muito contentes com o lançamento da plataforma LM4 Out–of–Band Management, que permite que nossos clientes utilizem a IA baseada em regras para recuperação e mitigação de infraestrutura de rede segura, confiável e automatizada”, disse Mathi Gurusamy, diretor de estratégia da Lantronix. “A Lantronix está empenhada em viabilizar a automação do gerenciamento de rede com soluções inovadoras que permitem que nossos clientes sejam mais eficientes, seguros e focados nos resultados.”

Os servidores de console serial alcançaram um mercado mundial de US $ 320 milhões em 2024 e estão crescendo a uma taxa constante de 7%, devendo chegar a US $ 391 milhões em 2026, de acordo com o Dell'Oro Group.

Out–of–Band Management em Todos os Lugares

Uma plataforma avançada de gerenciamento out–of–band, o LM4 pequeno, mas poderoso, fornece acesso, monitoramento contínuo e correção automatizada de problemas, bem como controle de dispositivos de infraestrutura de rede. Operacional independentemente de a rede estar ativa ou desativada, o sistema especializado usa IA baseada em regras para recuperar e mitigar automaticamente a infraestrutura de rede, com acesso confiável e seguro a equipamentos remotos durante uma interrupção. Com até quatro portas de conexões de console serial para gerenciamento direto de equipamentos, além de suporte para até 48 portas virtuais, o tamanho compacto e o preço acessível do LM4 permitem que os gerentes de rede utilizem out–of–band em todos os lugares, inclusive muitos locais anteriormente considerados muito pequenos e numerosos para gerenciamento out–of–band avançado.

Executando o poderoso software LMOS, o LM4 traz o poder do software baseado em NOC para a borda da rede para criar um plano de gerenciamento separado no rack com infraestrutura de rede. Com monitoramento contínuo e respostas automatizadas do runbook, o LM4 pode detectar e resolver problemas antes mesmo que as ferramentas tradicionais baseadas em NOC saibam que há um problema. Os LMOS contam com um modelo de autorização granular que se integra aos controles de acesso existentes, bem como às funções automatizadas de gerenciamento de alterações, inclusive a capacidade de armazenar vários arquivos de configuração e SO com backups locais para permitir a reversão automatizada de alterações de configuração com falha.

Padronização das Soluções da Série LM da Lantronix para OOB Management de Categoria Empresarial

O LM4 executa o mesmo software LMOS que os servidores de console LM83X e LM80, expandindo as opções de acesso ao console da Série LM de 2 a 104 portas. A Série LM é gerenciada centralmente pelo Lantronix Control Center, que está disponível para ser executado no local como uma VM ou hospedado na nuvem. Os produtos LM–Series da Lantronix permitem que os clientes padronizem seu gerenciamento out–of–band e implantem funcionalidades de nível empresarial e automação orientada por IA em todos os pontos da rede. O resultado é uma rede mais resiliente, mais fácil de gerenciar e com menos problemas, rolagens de caminhões de suporte reduzidas, e maior segurança e conformidade.

A Lantronix é a principal fonte de soluções out–of–band inovadoras, fornecendo um conjunto de plataformas confiáveis, seguras e fáceis de implantar, todas com suporte da sua excepcional equipe de serviço.

Também presentes na Cisco Live:

Soluções Out–of–Band Management

  • LM83X, que fornece out–of–band management orientado por IA de 8–104 dispositivos em conexões de console serial em um servidor de console escalável e robusto com entradas de energia duplas. 
  • LM80, que fornece uma solução out–of–band management serial de 8 portas que pode automatizar a maioria das tarefas rotineiras de manutenção e recuperação de TI de forma rápida e sem erros.
  • Lantronix Control Center, um único painel de vidro para gerenciar todos os dispositivos Lm–series para acesso remoto seguro, bem como para automatizar o gerenciamento de cada um dos dispositivos de infraestrutura de rede conectados. É uma fonte única para controles de Autorização–Autenticação–Contabilidade (Authorization–Authentication–Accounting – AAA), criando regras de monitoramento e ação sem scripts, com arquivamento central do sistema operacional do dispositivo monitorado e dos arquivos de configuração e relatórios de conformidade.

Gateways e Servidores de Console com Desempenho Confiável

  • EMG 8500, Gateway de Gerenciamento de Borda da Lantronix que fornece acesso remoto seguro para filiais, locais remotos, lojas de varejo ou qualquer lugar onde um gateway de dispositivo de rede externo seja necessário e o espaço seja limitado.
  • SLC 8000: Gerenciador de Console Avançado, fornecendo acesso seguro a equipamentos de TI com 8–48 portas de conexões de console RS–232 e USB.
  • Série G520, o gateway LTE CAT 4G e 5G celular de próxima geração da Lantronix projetado para aplicações industriais, inclusive Plataforma de Solução Percepxion™ Edge pré–ativado para aumentar a eficiência operacional e evitar ataques cibernéticos. 
  • Série X300, uma Solução de Gateway IoT Compacto Celular que inclui o hardware de gateway IoT da Lantronix e gerenciamento centralizado de dispositivos, dados celulares, segurança aprimorada e suporte técnico especializado em um pacote tudo–em–um.

Suporte Técnico Especializado

  • Serviços LEVEL Technical, fornecendo especialistas em suporte técnico dedicados para ajudar na implementação out–of–band e garantias limitadas de equipamentos vitalícios. 

Sobre a Lantronix

A Lantronix Inc. é líder global de soluções de IoT de computação e conectividade que visam mercados de alto crescimento, incluindo Smart Cities, Enterprise e Transportation. Os produtos e serviços da Lantronix capacitam as empresas a alcançar o sucesso nos mercados de IoT em crescimento, fornecendo soluções personalizáveis que capacitam AI Edge Intelligence. As soluções avançadas da Lantronix incluem infraestrutura de Subestações Inteligentes, sistemas de Infotainment e Vigilância por Vídeo, complementados com o avançado Out–of–Band Management (OOB) para Cloud e Edge Computing.

Para mais informação, visite Site da Lantronix.

“Declaração Safe Harbor sob a Lei Private Securities Litigation Reform Act de 1995: Este comunicado contém declarações de previsão de acordo com as leis federais de valores mobiliários, incluindo, sem limitação, declarações relacionadas à liderança da Lantronix. Essas declarações de previsão são baseadas nas nossas expectativas atuais e estão sujeitas a riscos e incertezas substanciais que podem fazer com que nossos resultados reais, negócios futuros, condição financeira ou desempenho, sejam substancialmente diferentes dos nossos resultados históricos, expressos ou implícitos, em qualquer declaração prospectiva contida neste comunicado de imprensa. Os riscos e incertezas potenciais incluem, mas não estão limitados a, fatores tais como os efeitos das condições econômicas regionais e mundiais negativas ou piores, ou instabilidade do mercado nos nossos negócios, incluindo efeitos sobre as decisões de compra por parte dos nossos clientes; nossa capacidade de mitigar qualquer interrupção nas cadeias de fornecimento dos nossos fornecedores devido à pandemia de COVID–19 ou outros surtos, guerras e tensões recentes na Europa, Ásia e Oriente Médio, ou outros fatores; respostas futuras e efeitos de crises de saúde pública; riscos de segurança cibernética; mudanças nas leis, regulamentos e tarifas aplicáveis do governo dos EUA e de outros países; nossa capacidade de implementar com sucesso nossa estratégia de aquisições ou integrar as empresas adquiridas; dificuldades e custos com a proteção de patentes e outros direitos de propriedade; nível da nossa dívida, nossa capacidade de lidar com a nossa dívida e as restrições nos nossos contratos de dívida; e quaisquer fatores adicionais incluídos no nosso Relatório Anual no Formulário 10–K do exercício fiscal encerrado em 30 de junho de 2024, arquivado na Comissão de Valores Mobiliários (a “SEC”) em 9 de setembro de 2024, incluindo na seção intitulada “Fatores de Risco” no Item 1A da Parte I de tal relatório, bem como nos nossos outros registros públicos na SEC. Fatores de risco adicionais podem ser identificados ocasionalmente nos nossos futuros documentos. Além disso, os resultados reais podem ser diferentes devido aos riscos e incertezas adicionais que não sejam do nosso conhecimento no momento ou que não sejam considerados como relevantes para os nossos negócios. Devido a tudo isso, os investidores não devem depositar confiança indevida em qualquer declaração voltada para o futuro. As declarações de previsão que fazemos são válidas somente a partir da data em que são feitas. Rejeitamos expressamente qualquer intenção ou obrigação de atualizar qualquer declaração de previsão a partir da data de hoje para adequar tais declarações a resultados reais ou mudanças na nossa opinião ou expectativas, exceto conforme exigido por lei ou pelas regras da Nasdaq Stock Market, LLC. Caso façamos alguma atualização ou correção de quaisquer declarações de previsão, os investidores não devem inferir que faremos outras atualizações ou correções.

©2025 Lantronix, Inc. Todos os direitos reservados. Lantronix é uma marca comercial registrada. Todas as outras marcas comerciais são de propriedade de seus respectivos proprietários.

Contato de Mídia da Lantronix:
Gail Kathryn Miller
Gerente de Marketing e
Comunicações Corporativas
[email protected]

Contato para Analista e Investidor da Lantronix:
[email protected]

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/bce840fa–a24a–413e–96ca–23443e7d1d6b


GLOBENEWSWIRE (Distribution ID 9353311)

Lantronix stellt auf der Cisco Live erstmals die neue LM4-Out-of-Band-Management-Plattform mit KI-Unterstützung vor

IRVINE, Kalifornien, Feb. 05, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), ein weltweit führender Anbieter von Rechen– und Konnektivitätslösungen für IoT–Lösungen, die KI–Edge–Intelligenz ermöglichen, wird seine neue LM4–Plattform für das Out–of–Band–Management (OOBM) mit KI–Unterstützung am Stand A10 während der Cisco Live vom 10. bis 14. Februar 2025 im Amsterdam RAI vorstellen. Der LM4 von Lantronix ist der erste Konsolenserver der Branche, der speziell für Intermediate Distribution Frames (IDFs) und kompakte Umgebungen wie Geldautomaten, Kioske und Netzwerk–Aggregationspunkte entwickelt, dimensioniert und bepreist wurde. Der LM4 wurde für das Gesundheitswesen, den Finanzsektor, Versorgungsunternehmen, Telekommunikationsunternehmen, Behörden, den Einzelhandel und die Fertigungsindustrie entwickelt und bietet Automatisierungs–, Compliance– und Cybersicherheitsfunktionen auf Unternehmensebene, wobei er auf Technologien zurückgreift, die sich in militärischen und finanziellen Netzwerken bewährt haben.

„Wir freuen uns, die Out–of–Band–Management–Plattform LM4 vorstellen zu können, die es unseren Kunden ermöglicht, regelbasierte KI für eine sichere, zuverlässige und automatisierte Wiederherstellung und Schadensbegrenzung der Netzwerkinfrastruktur zu nutzen“, so Mathi Gurusamy, Chief Strategy Officer bei Lantronix. „Bei Lantronix haben wir uns der Automatisierung des Netzwerkmanagements mit innovativen Lösungen verschrieben, die es unseren Kunden ermöglichen, effizienter, sicherer und gewinnorientierter zu arbeiten.“

Serielle Konsolenserver stellten im Jahr 2024 einen weltweiten Markt von 320 Millionen US–Dollar dar und wachsen laut der Dell'Oro Group mit einer konstanten Rate von 7 Prozent auf voraussichtlich 391 Millionen US–Dollar im Jahr 2026.

Out–of–Band–Management überall

Als fortschrittliche Out–of–Band–Management–Plattform bietet die kleine, aber leistungsstarke LM4 Zugriff, kontinuierliche Überwachung und automatische Behebung von Problemen sowie die Steuerung von Netzwerkinfrastrukturgeräten. Das Expertensystem ist unabhängig davon, ob das Netzwerk verfügbar ist oder nicht, einsatzbereit und nutzt regelbasierte KI, um die Netzwerkinfrastruktur automatisch wiederherzustellen und zu schützen, einschließlich eines zuverlässigen und sicheren Zugriffs auf Remote–Geräte während eines Ausfalls. Mit bis zu vier seriellen Konsolenanschlüssen für die direkte Verwaltung von Geräten und Unterstützung für bis zu 48 virtuelle Ports ermöglicht die kompakte Größe und der erschwingliche Preis der LM4 Netzwerkmanagern die Nutzung von Out–of–Band überall, auch an vielen Standorten, die bisher als zu klein und zahlreich für eine fortschrittliche Out–of–Band–Verwaltung galten.

Mit der leistungsstarken LMOS–Software bringt die LM4 die Leistungsfähigkeit von NOC–basierter Software an den Rand des Netzwerks, um eine separate Verwaltungsebene im Rack mit Netzwerkinfrastruktur zu schaffen. Durch kontinuierliche Überwachung und automatisierte Runbook–Antworten kann die LM4 Probleme erkennen und lösen, bevor herkömmliche NOC–basierte Tools überhaupt wissen, dass ein Problem vorliegt. LMOS verfügt über ein granulares Autorisierungsmodell, das sich in bestehende Zugriffskontrollen integrieren lässt, sowie über automatisierte Änderungsmanagementfunktionen, einschließlich der Möglichkeit, mehrere Konfigurations– und Betriebssystemdateien mit lokalen Backups zu speichern, um ein automatisiertes Rollback fehlgeschlagener Konfigurationsänderungen zu ermöglichen.

Standardisieren Sie auf Lösungen der Lantronix LM–Serie für die unternehmensweite Verwaltung von OOB

Die LM4 läuft mit derselben LMOS–Software wie die LM83X– und LM80–Konsolenserver und erweitert die Konsolenzugriffsoptionen der LM–Serie auf 2 bis 104 Ports. Die LM–Serie wird zentral über das Lantronix Control Center verwaltet, das vor Ort als VM ausgeführt oder in der Cloud gehostet werden kann. Die Produkte der LM–Serie von Lantronix ermöglichen es Kunden, ihr Out–of–Band–Management zu standardisieren und an allen Punkten im Netzwerk Funktionen auf Unternehmensebene und KI–gesteuerte Automatisierung einzusetzen. Das Ergebnis ist ein widerstandsfähigeres Netzwerk, das einfacher zu verwalten ist, weniger Probleme verursacht, weniger Support–Einsätze erfordert und eine höhere Sicherheit und Compliance bietet.

Lantronix ist die erste Anlaufstelle für innovative Out–of–Band–Lösungen und bietet eine Reihe zuverlässiger, sicherer und einfach zu implementierender Plattformen, die alle von seinem hervorragenden Serviceteam unterstützt werden.

Außerdem werden auf der Cisco Live gezeigt:

Out–of–Band–Management–Lösungen

  • LM83X, die KI–gesteuertes Out–of–Band–Management von 8–104 Geräten über serielle Konsolenverbindungen in einem skalierbaren und robusten Konsolenserver mit zwei Stromeingängen ermöglicht. 
  • LM80 bietet eine serielle, AI–gesteuerte Out–of–Band–Verwaltungslösung mit acht festen Ports, die einen Großteil der routinemäßigen IT–Wartungs– und Wiederherstellungsaufgaben schnell und fehlerfrei automatisieren kann.
  • Lantronix Control Center, eine einzige Benutzeroberfläche für die Verwaltung aller Geräte der LM–Serie für sicheren Fernzugriff sowie für die automatisierte Verwaltung jedes der angeschlossenen Netzwerkinfrastrukturgeräte. Es handelt sich um eine einzige Quelle für AAA–Kontrollen (Authorization–Authentication–Accounting), die die Erstellung von Überwachungs– und Aktionsregeln ohne Skripterstellung, die zentrale Archivierung sowohl des überwachten Gerätebetriebssystems als auch der Konfigurationsdateien und die Erstellung von Compliance–Berichten ermöglicht.

Zuverlässige Gateways und Konsolenserver mit bewährter Leistung

  • EMG 8500, das Edge Management Gateway von Lantronix, das einen sicheren Fernzugriff für Zweigstellen, entfernte Standorte, Stores oder überall dort ermöglicht, wo ein externes Netzwerk–Geräte–Gateway benötigt wird und der Platz begrenzt ist.
  • SLC 8000: Advanced Console Manager, bietet sicheren Zugriff auf IT–Geräte mit 8–48 Ports für RS–232– und USB–Konsolenverbindungen.
  • G520 Series, Lantronix LTE–CAT–4G– und 5G–Gateway der nächsten Generation für das Internet der Dinge (IoT) für industrielle Anwendungen, einschließlich der voraktivierten Percepxion™ Edge Solution Platform, um die betriebliche Effizienz zu steigern und Cyberangriffe zu verhindern. 
  • X300 Series, eine kompakte IoT–Gateway–Lösung für Mobilfunk, die die IoT–Gateway–Hardware von Lantronix und eine zentralisierte Geräteverwaltung, Mobilfunkdaten, verbesserte Sicherheit und technischen Support durch Experten in einem Komplettpaket vereint.

Technischer Support durch Experten

  • LEVEL Technical Services stellt engagierte technische Support–Experten zur Verfügung, die bei der Implementierung von Out–of–Band–Einsätzen und begrenzten lebenslangen Gerätegarantien helfen. 

Über Lantronix

Lantronix Inc. ist ein weltweit führender Anbieter von IoT–Lösungen für Rechenleistung und Konnektivität, die auf wachstumsstarke Märkte wie Smart Cities, Unternehmen und Transportwesen abzielen. Die Produkte und Dienstleistungen von Lantronix ermöglichen es Unternehmen, auf den wachsenden IoT–Märkten erfolgreich zu sein, indem sie anpassbare Lösungen bereitstellen, die KI–Edge–Intelligenz ermöglichen. Zu den fortschrittlichen Lösungen von Lantronix gehören die Infrastruktur für intelligente Umspannwerke, Infotainmentsysteme und Videoüberwachung, ergänzt durch fortschrittliches Out–of–Band–Management (OOB) für Cloud– und Edge–Computing.

Weitere Informationen finden Sie auf der Website von Lantronix.

„Safe Harbor“–Erklärung gemäß dem Private Securities Litigation Reform Act von 1995: Diese Pressemitteilung enthält zukunftsgerichtete Aussagen im Sinne der US–Bundeswertpapiergesetze, einschließlich, aber nicht beschränkt auf Aussagen zur Geschäftsführung von Lantronix. Diese zukunftsgerichteten Aussagen basieren auf unseren aktuellen Erwartungen und unterliegen erheblichen Risiken und Ungewissheiten, die dazu führen können, dass unsere tatsächlichen Ergebnisse, zukünftigen Geschäfts–, Finanz– oder Leistungsergebnisse erheblich von unseren historischen Ergebnissen oder von denen, die in den zukunftsgerichteten Aussagen in dieser Pressemitteilung ausgedrückt oder impliziert werden, abweichen. Zu den potenziellen Risiken und Ungewissheiten gehören unter anderem Faktoren wie die Auswirkungen negativer oder sich verschlechternder regionaler und weltweiter wirtschaftlicher Bedingungen oder Marktinstabilität auf unser Geschäft, einschließlich der Auswirkungen auf die Kaufentscheidungen unserer Kunden; unsere Fähigkeit, Unterbrechungen in unseren Lieferketten und denen unserer Zulieferer und Verkäufer aufgrund der COVID–19–Pandemie oder anderer Ausbrüche, Kriege und jüngster Spannungen in Europa, Asien und dem Nahen Osten oder anderer Faktoren abzumildern; künftige Reaktionen auf und Auswirkungen von Krisen im Bereich der öffentlichen Gesundheit; Risiken im Bereich der Cybersicherheit; Änderungen geltender US–amerikanischer und ausländischer Cybersicherheitsrisiken; Änderungen der geltenden Gesetze, Vorschriften und Zölle der US–amerikanischen und ausländischer Regierungen; unsere Fähigkeit, unsere Übernahmestrategie erfolgreich umzusetzen oder erworbene Unternehmen zu integrieren; Schwierigkeiten und Kosten des Schutzes von Patenten und anderen Eigentumsrechten; die Höhe unserer Verschuldung, unsere Fähigkeit, unsere Verschuldung zu bedienen, und die Beschränkungen in unseren Schuldverträgen; sowie alle weiteren Faktoren, die in unserem Jahresbericht auf Formblatt 10–K für das am 30. Juni 2024 zu Ende gegangene Geschäftsjahr enthalten sind, der am 9. September 2024 bei der Securities and Exchange Commission (die „SEC“) eingereicht wurde, einschließlich des Abschnitts „Risikofaktoren“ in Punkt 1A von Teil I dieses Berichts, sowie in unseren anderen öffentlichen Einreichungen bei der SEC. Weitere Risikofaktoren können von Zeit zu Zeit in unseren zukünftigen Veröffentlichungen genannt werden. Darüber hinaus können die tatsächlichen Ergebnisse aufgrund zusätzlicher Risiken und Unsicherheiten, die uns derzeit nicht bekannt sind oder die wir derzeit als nicht wesentlich für unser Geschäft einschätzen, abweichen. Aus diesen Gründen sind die Anleger dazu angehalten, zukunftsgerichtete Aussagen mit der gebotenen Vorsicht zur Kenntnis zu nehmen. Die in dieser Mitteilung enthaltenen zukunftsgerichteten Aussagen beziehen sich ausschließlich auf den Zeitpunkt ihrer Veröffentlichung. Wir lehnen ausdrücklich jede Absicht oder Verpflichtung ab, zukunftsgerichtete Aussagen nach diesem Datum zu aktualisieren, es sei denn, dies ist gesetzlich vorgeschrieben oder durch die Regeln der Nasdaq Stock Market LLC festgelegt. Wenn wir zukunftsgerichtete Aussagen aktualisieren oder korrigieren, sollten Anleger nicht davon ausgehen, dass wir weitere Aktualisierungen oder Korrekturen vornehmen werden.

© 2025 Lantronix, Inc. Alle Rechte vorbehalten. Lantronix ist eine eingetragene Marke. Andere Marken und Markennamen sind Eigentum der jeweiligen Inhaber.

Lantronix–Medienkontakt:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
[email protected]

Lantronix – Analysten– und Anlegerkontakt:
[email protected]

Ein Foto zu dieser Mitteilung finden Sie unter https://www.globenewswire.com/NewsRoom/AttachmentNg/bce840fa–a24a–413e–96ca–23443e7d1d6b


GLOBENEWSWIRE (Distribution ID 9353311)

Lantronix présentera sa nouvelle plateforme de gestion hors bande LM4 alimentée par l’IA au salon Cisco Live

IRVINE, Californie, 05 févr. 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ : LTRX), un leader mondial du calcul et de la connectivité pour les solutions IoT permettant l’intelligence en périphérie du réseau (AI Edge), présentera sa nouvelle plateforme LM4 de gestion hors bande (OOBM) alimentée par l’IA au stand A10 du salon Cisco Live, qui se déroule du 10 au 14 février 2025 au centre de conférences RAI d’Amsterdam. La plateforme LM4 de Lantronix est le premier serveur de console du secteur spécifiquement conçu, calibré et tarifé pour les répartiteurs intermédiaires (IDF) et les environnements compacts tels que les distributeurs automatiques de billets, les kiosques et les points d’agrégation de réseau. Destinée aux secteurs de la santé, de la finance, des services publics, des télécommunications, des administrations publiques, de la vente au détail et des industries manufacturières, la plateforme LM4 offre des capacités d’automatisation, de conformité et de cybersécurité de niveau professionnel, en s’appuyant sur une technologie éprouvée dans les réseaux militaires et financiers.

« Nous sommes ravis de présenter la plateforme de gestion hors bande LM4, qui permet à nos clients d’exploiter une intelligence artificielle basée sur des règles pour une restauration et une atténuation sécurisées, fiables et automatisées de l’infrastructure du réseau », a déclaré Mathi Gurusamy, responsable de la stratégie chez Lantronix. « Nous mettons tout en œuvre chez Lantronix pour permettre l’automatisation de la gestion réseau grâce à des solutions innovantes qui apportent à nos clients une plus grande efficacité et une meilleure sécurité afin de rester concentrés sur les résultats ».

Selon un rapport de Dell’Oro Group, les serveurs de console série représentaient un marché mondial de 320 millions de dollars en 2024 et leur croissance se maintient à un taux de 7 % avec une projection de 391 millions de dollars en 2026.

Généralisation de la gestion hors bande

Petite mais puissante, la LM4 est une plateforme avancée de gestion hors bande qui permet l’accès au réseau, la surveillance continue et la résolution automatisée des problèmes, ainsi que le contrôle des dispositifs de l’infrastructure du réseau. Restant opérationnel quel que soit l’état de fonctionnement du réseau, ce système expert utilise l’IA basée sur des règles pour restaurer l’infrastructure du réseau et en atténuer les défaillances automatiquement, assurant également un accès fiable et sécurisé à l’équipement distant pendant une panne. Grâce à ses quatre ports de connexion de console série pour la gestion directe des équipements et à la prise en charge de 48 ports virtuels, la taille compacte et le prix abordable de la plateforme LM4 permettent aux gestionnaires de réseau de bénéficier d’une gestion hors bande généralisée, y compris dans des sites jusqu’alors considérés comme trop petits et trop nombreux pour une gestion hors bande évoluée.

Exécutant le puissant logiciel LMOS, la plateforme LM4 apporte la puissance du logiciel de gestion de réseau (NOC) à la périphérie du réseau pour créer un plan de gestion séparé dans le rack avec l’infrastructure du réseau. Grâce à une surveillance continue et à des guides de réponses automatisées, LM4 peut détecter et résoudre les problèmes avant même que les outils NOC traditionnels en aient connaissance. Le logiciel LMOS propose un modèle d’autorisation granulaire qui s’intègre aux contrôles d’accès existants, ainsi que des fonctions de gestion automatisée des changements, y compris la possibilité de stocker plusieurs fichiers de configuration et de système d’exploitation avec des sauvegardes locales pour permettre une restauration automatique de la configuration en cas d’échec.

Standardisation grâce aux solutions de la série LM de Lantronix pour une gestion OOB de niveau professionnel

La plateforme LM4 exécute le même logiciel LMOS que les serveurs de console LM83X et LM80, ce qui élargit les options d’accès aux consoles de la série LM de 2 à 104 ports. La série LM est gérée de manière centralisée par le Lantronix Control Center, qui peut être installé sur site en tant que machine virtuelle ou hébergé dans le cloud. Les produits Lantronix de la série LM permettent aux clients de standardiser leur gestion hors bande et de déployer des fonctionnalités de niveau professionnel et une automatisation pilotée par l’IA à tous les points du réseau. Ainsi, le réseau est plus résilient et plus facile à gérer, avec moins de problèmes, une réduction du nombre de déplacements des techniciens de support et un renforcement de la sécurité et de la conformité.

Lantronix est la source privilégiée de solutions hors bande innovantes, offrant une suite de plateformes fiables, sécurisées et faciles à déployer, toutes soutenues par une équipe de service exceptionnelle.

Autres solutions présentées à Cisco Live :

Solutions de gestion hors bande

  • LM83X, une solution de gestion hors bande pilotée par l’IA de 8 à 104 appareils via des connexions de console série dans un serveur de console évolutif et robuste avec deux entrées d’alimentation. 
  • LM80, une solution de gestion hors bande fixe à 8 ports série pilotée par l’IA qui permet d’automatiser rapidement et sans erreur la majorité des tâches courantes de maintenance et de restauration des systèmes d’information.
  • Lantronix Control Center, une interface unique pour la gestion de tous les appareils de la série LM permettant un accès à distance sécurisé ainsi que l’automatisation de la gestion de chacun des appareils d’infrastructure de réseau connectés. Il s’agit d’une source unique pour les contrôles d’autorisation, d’authentification et de traçabilité (AAA), la création de règles de surveillance et d’action sans script, l’archivage centralisé du système d’exploitation et des fichiers de configuration des appareils surveillés, et les rapports de conformité.

Passerelles et serveurs de console fiables et performants

  • EMG 8500, la passerelle de gestion périphérique (Edge) de Lantronix qui offre un accès à distance sécurisé pour les succursales, les sites distants, les magasins de détail ou tout autre site où une passerelle de périphériques réseau hors site est nécessaire et où l’espace est limité.
  • SLC 8000: Advanced Console Manager, un gestionnaire de console avancé fournissant un accès sécurisé à l’équipement informatique avec 8 à 48 ports de connexions de console RS–232 et USB.
  • G520 Series, une passerelle cellulaire IoT LTE CAT 4G et 5G de nouvelle génération, conçue par Lantronix pour les applications industrielles, y compris la Percepxion™ Edge Solution Platform préactivée pour accroître l’efficacité opérationnelle et prévenir les cyber–attaques. 
  • X300 Series, une solution de passerelle IoT compacte cellulaire qui comprend le matériel de passerelle IoT de Lantronix et la gestion centralisée des appareils, des données cellulaires, une sécurité renforcée et une assistance technique spécialisée dans une formule tout–en–un.

Assistance technique spécialisée

  • LEVEL Technical Services, fournissant des experts en support technique dédiés pour aider à la mise en œuvre des déploiements hors bande et des garanties à vie limitées sur l’équipement. 

À propos de Lantronix

Lantronix Inc. est un leader mondial des solutions IoT de calcul et de connectivité destinées aux secteurs à forte croissance, notamment l’urbanisme intelligent, les entreprises et les transports. Les produits et services de Lantronix permettent aux entreprises de se démarquer sur les marchés de l’IoT en plein essor en proposant des solutions personnalisables qui exploitent l’intelligence artificielle en périphérie (AI Edge Intelligence). Les solutions de pointe développées par Lantronix comprennent une infrastructure de sous–stations intelligentes, des systèmes d’infodivertissement et de surveillance vidéo, mais également une administration hors bande (OOB) avancée adaptée au cloud et à l’informatique en périphérie.

Pour en savoir plus, consultez le site Internet de Lantronix.

Déclaration prospective au sens de la loi américaine Private Securities Litigation Reform Act de 1995 : le présent communiqué de presse contient des déclarations prospectives au sens des lois fédérales sur les valeurs mobilières, y compris, sans toutefois s’y limiter, des déclarations sur le leadership de Lantronix. Ces déclarations prospectives sont fondées sur nos attentes actuelles et sont assujetties à des risques et incertitudes importants qui pourraient faire différer nos résultats réels, notre activité future, notre situation financière ou nos performances de nos résultats historiques ou de ceux exprimés ou induits dans toute déclaration prospective contenue dans ce communiqué de presse. Ces risques et incertitudes comprennent, entre autres, des facteurs tels que les effets négatifs ou la dégradation de la situation économique régionale et mondiale ou l’instabilité du marché ciblant nos activités, y compris les effets sur les décisions d’achat de nos clients ; notre capacité à atténuer toute perturbation de nos propres chaînes d’approvisionnement et de celles de nos fournisseurs et distributeurs induite par la pandémie de COVID–19 ou d’autres épidémies ; les guerres et tensions récentes en Europe, en Asie et au Moyen–Orient, ou d’autres facteurs semblables ; les réponses à venir et les conséquences des crises de santé publique ; les risques en matière de cybersécurité ; les modifications apportées aux lois, réglementations et droits de douane en vigueur aux États–Unis et dans les pays étrangers ; notre aptitude à mettre en œuvre avec succès notre stratégie d’acquisition ou d’intégration des entreprises rachetées ; les enjeux et frais liés à la protection des droits de brevet et autres droits de propriété ; notre niveau d’endettement; notre capacité à rembourser notre dette et les restrictions imposées à nos accords de dette ; ainsi que tout autre facteur supplémentaire repris dans notre rapport annuel sous le formulaire 10–K pour l’exercice clos le 30 juin 2024, déposé auprès de la Securities and Exchange Commission (la « SEC ») le 9 septembre 2024 dernier, y compris à la rubrique « Facteurs de risque » sous l’alinéa 1A de la Partie I de ce rapport, ainsi que dans nos autres documents publics déposés auprès de la SEC. Des facteurs de risque supplémentaires peuvent être identifiés le cas échéant dans nos futurs dépôts. Par ailleurs, les résultats réels peuvent varier en raison de risques et incertitudes supplémentaires dont nous n’avons pas nécessairement conscience à ce jour ou que nous ne considérons pas comme majeurs pour nos activités. En conséquence, il est recommandé aux investisseurs de ne pas se fier indûment aux déclarations prospectives, lesquelles ne sont valables qu’à leur date de publication. Nous déclinons expressément toute intention ou obligation de les mettre à jour postérieurement à ce communiqué en vue de les adapter selon nos résultats réels ou les revirements intervenus dans nos avis ou attentes, sauf si la loi applicable ou les règles du Nasdaq Stock Market LLC l’exigent. Si nous actualisons ou corrigeons l’une quelconque de ces déclarations, les investisseurs ne sauraient tenir d’autres mises à jour ou révisions pour garanties.

© 2025 Lantronix, Inc. Tous droits réservés. Lantronix est une marque déposée. Les autres marques et noms commerciaux appartiennent à leurs détenteurs respectifs.

Contact médias — Lantronix :
Gail Kathryn Miller
Responsable du marketing et de la
communication
[email protected]

Contact analystes et investisseurs — Lantronix :
[email protected]

Une photo accompagnant cette annonce est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/bce840fa–a24a–413e–96ca–23443e7d1d6b


GLOBENEWSWIRE (Distribution ID 9353311)

Lantronix to Debut New LM4 AI-Powered Out-of-Band Management Platform at Cisco Live

IRVINE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling AI Edge intelligence, will debut its new LM4 AI–powered Out–of–Band Management (OOBM) platform at Stand A10 during Cisco Live, February 10–14, 2025, at Amsterdam RAI. Lantronix’s LM4 is the industry’s first console server specifically designed, sized and priced for Intermediate Distribution Frames (IDFs) and compact environments such as ATMs, kiosks, and network aggregation points. Engineered for healthcare, finance, utilities, telecommunications, government, retail and manufacturing, the LM4 delivers enterprise–grade automation, compliance and cybersecurity capabilities, leveraging technology proven in military and financial networks.

“We’re excited to introduce the LM4 Out–of–Band Management platform, which enables our customers to leverage rules–based AI for secure, reliable and automated network infrastructure recovery and mitigation,” said Mathi Gurusamy, chief strategy officer at Lantronix. “At Lantronix, we are committed to enabling network management automation with innovative solutions that enable our customers to be more efficient, secure and bottom–line focused.”

Serial console servers represented a $320 million worldwide market in 2024 and are growing at a steady 7 percent rate to a projected $391 million in 2026, according to the Dell’Oro Group.

Out–of–Band Management Everywhere

An advanced out–of–band management platform, the small yet powerful LM4 provides access, continuous monitoring and automated remediation of issues as well as control of network infrastructure devices. Operational whether the network is up or down, the expert system uses rules–based AI to recover and mitigate network infrastructure automatically, including reliable and secure access to remote gear during an outage. With up to four ports of serial console connections for directly managing gear plus support for up to 48 virtual ports, the LM4’s compact size and affordable price enables network managers to utilize out–of–band everywhere, including many locations previously considered too small and numerous for advanced out–of–band management.

Running the powerful LMOS software, the LM4 brings the power of NOC–based software to the network’s edge to create a separate management plane in the rack with network infrastructure. With continuous monitoring and automated runbook responses, the LM4 can detect and solve issues before traditional NOC–based tools even know there is an issue. LMOS features a granular authorization model that integrates with existing access controls as well as automated change management functions, including the ability to store multiple config and OS files with local backups to enable automated rollback of failed config changes.

Standardize on Lantronix LM–Series Solutions for Enterprise–Grade OOB Management

The LM4 runs the same LMOS software as the LM83X and LM80 console servers, expanding the LM–Series console access options anywhere from 2–104 ports. The LM–Series is centrally managed by the Lantronix Control Center, which is available to run on–premises as a VM or hosted in the cloud. Lantronix’s LM–Series products allow customers to standardize their out–of–band management and deploy enterprise–grade functionality and AI–driven automation at all points in the network. The result is a more resilient network that’s easier to manage with fewer issues, reduced support truck rolls and stronger security and compliance.

Lantronix is the go–to source for innovative out–of–band solutions, providing a suite of reliable, secure and easy–to–deploy platforms, all supported by its exceptional service team.

Also being shown at Cisco Live are:

Out–of–Band Management Solutions

  • LM83X, delivering AI–driven out–of–band management of 8–104 devices over serial console connections in a scalable and robust console server with dual power inputs. 
  • LM80, providing a fixed 8–port serial AI–driven out–of–band management solution that can automate a majority of routine IT maintenance and recovery tasks quickly and error–free.
  • Lantronix Control Center, a single pane of glass for managing all LM–series devices for secure remote access as well as for automating management of each of the connected network infrastructure devices. It is a single source for Authorization–Authentication–Accounting (AAA) controls, creating monitoring and action rules without scripting, centrally archiving both monitored device operating system and configuration files and compliance reporting.

Reliable Gateways and Console Servers With Trusted Performance

  • EMG 8500, Lantronix’s Edge Management Gateway that provides secure remote access for branch offices, remote locations, retail stores or anywhere an offsite network device gateway is needed and where space is limited.
  • SLC 8000: Advanced Console Manager, providing secure access to IT equipment with 8–48 ports of RS–232 and USB console connections.
  • G520 Series, Lantronix’s next–generation IoT cellular LTE CAT 4G and 5G gateway designed for industrial applications, including pre–enabled Percepxion™ Edge Solution Platform to increase operational efficiency and prevent cyber–attacks. 
  • X300 Series, a Cellular Compact IoT Gateway Solution that includes Lantronix’s IoT gateway hardware and centralized device management, cellular data, enhanced security and expert technical support in an all–in–one package.

Expert Technical Support

  • LEVEL Technical Services, providing dedicated technical support experts to assist with implementing out–of–band deployments and limited lifetime equipment warranties. 

About Lantronix

Lantronix Inc. is a global leader of compute and connectivity IoT solutions that target high–growth markets, including Smart Cities, Enterprise and Transportation. Lantronix’s products and services empower companies to succeed in the growing IoT markets by delivering customizable solutions that enable AI Edge Intelligence. Lantronix’s advanced solutions include Intelligent Substations infrastructure, Infotainment systems and Video Surveillance, supplemented with advanced Out–of–Band Management (OOB) for Cloud and Edge Computing.

For more information, visit the Lantronix website.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward–looking statements within the meaning of federal securities laws, including, without limitation, statements related to Lantronix leadership. These forward–looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward–looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to the COVID–19 pandemic or other outbreaks, wars and recent tensions in Europe, Asia and the Middle East, or other factors; future responses to and effects of public health crises; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10–K for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on Sept. 9, 2024, including in the section entitled “Risk Factors” in Item 1A of Part I of that report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward–looking statements. The forward–looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward–looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the Nasdaq Stock Market LLC. If we do update or correct any forward–looking statements, investors should not conclude that we will make additional updates or corrections.

©2025 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
[email protected]

Lantronix Analyst and Investor Contact:
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bce840fa–a24a–413e–96ca–23443e7d1d6b


GLOBENEWSWIRE (Distribution ID 9352539)

Zoom to Release Financial Results for the Fourth Quarter and Full Fiscal Year 2025

SAN JOSE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the fourth quarter and full fiscal year 2025 on Monday, February 24, 2025, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
[email protected]

Investor Relations
Charles Eveslage
Head of Investor Relations for Zoom
[email protected]


GLOBENEWSWIRE (Distribution ID 9350562)

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical–stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology–based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.

A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical–stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology–based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self–administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:

Matthew Osborne

Investor Relations and Corporate Communications
[email protected]

Media Contact:
Argot Partners

[email protected]


GLOBENEWSWIRE (Distribution ID 9348330)